Reference number(s)
4548-A

Standard Medicare Part B Management Cosela

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over the counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Cosela	trilaciclib

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indication[1]

COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

Compendial Use[2]

Prophylaxis of chemotherapy-induced anemia

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this policy should be accompanied by supporting evidence from Medicare approved compendia.

Coverage Criteria

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Extensive-Stage Small Cell Lung Cancer

Authorization of 6 months may be granted to decrease the incidence of chemotherapy-induced myelosuppression or anemia and red blood cell transfusions in adult patients with extensive-stage small cell lung cancer when all of the following criteria are met:

- The member will be receiving either of the following chemotherapeutic regimens:
    - A platinum/etoposide-containing regimen.
    - A topotecan-containing regimen.
- The requested medication will be given within 4 hours prior to the start of chemotherapy on each day chemotherapy is administered.
- The requested medication will not be used with granulocyte colony-stimulating factors (G-CSFs) and/or erythropoiesis-stimulating agents (ESAs) as primary prophylaxis during cycle 1.

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 6 months may be granted when all of the following criteria are met:

- The member is currently receiving therapy with the requested medication.
- The requested medication is being used to treat an indication listed in the Coverage Criteria section.
- The member is receiving benefit from therapy.

Summary of Evidence

The contents of this policy were created after examining the following resources:

- The prescribing information for Cosela
- The available compendium
    - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
    - Micromedex DrugDex
    - American Hospital Formulary Service- Drug Information (AHFS-DI)
    - Lexi-Drugs
    - Clinical Pharmacology
- NCCN Guideline: Hematopoietic growth factors

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Cosela are covered as well as prophylaxis of chemotherapy-induced anemia in patients who will receive a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Explanation of Rationale

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

Support for using Cosela to decrease the incidence of anemia from chemotherapy can be found in the National Comprehensive Cancer Network's guideline for hematopoietic growth factors. The NCCN Guideline supports the use of Cosela as a prophylactic option to decrease the incidence of anemia and red blood cell transfusions when administered before platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

References

1. Cosela [package insert]. Morristown, NJ: Pharmacosmos Therapeutics Inc.; August 2025.
2. The NCCN Drugs & Biologics Compendium® © 2026 National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org. Accessed January 13, 2026.

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.